×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| GLENMARK PHARMACEUTICALS LTD. | 24642.63 | 3302.26 | 23949.28 | 11.7 | 59,708 | 44.8 |
| BIOCON LTD. | 5984.0 | -83.0 | 5371.0 | -0.07 | 48746 | 135.0 |
| Laurus Labs Limited | 14542.7 | 1579.4 | 14327.5 | 2.93 | 48325 | 95.0 |
Glenmark Pharmaceuticals ltd, with Security Code 532296, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,939.0 | 2,144.4 | 2,233.4 | 1,365.1 | 2,148.2 | 2,329.5 | 2,636.1 | 2,251.3 | 2,009.5 | 2,394.9 |
| Expenses | 1,721.4 | 1,659.4 | 1,789.9 | 1,549.4 | 1,650.8 | 1,698.4 | 1,857.5 | 1,757.4 | 1,668.9 | 1,666.8 |
| Operating Profit | 217.7 | 485.0 | 443.5 | -184.3 | 497.4 | 631.1 | 778.6 | 493.9 | 340.5 | 728.2 |
| OPM % | 11.23% | 22.62% | 19.86% | -13.5% | 23.16% | 27.09% | 29.54% | 21.94% | 16.95% | 30.4% |
| Other Income | -425.4 | 17.7 | 53.9 | 233.5 | 5,933.2 | 55.6 | 83.1 | 129.2 | -90.7 | -253.9 |
| Interest | 58.9 | 61.9 | 58.2 | 73.6 | 83.4 | 15.3 | 11.8 | 8.5 | 13.1 | 15.5 |
| Depreciation | 46.7 | 48.8 | 49.8 | 51.2 | 52.4 | 53.1 | 54.8 | 55.2 | 55.5 | 57.6 |
| Profit before tax | 345.0 | 423.7 | 409.0 | -50.2 | 1,147.9 | 618.3 | 795.1 | 559.5 | 360.3 | 724.4 |
| Tax % | -56.1% | -30.7% | -22.3% | -73% | -26.7% | -26.6% | -25.2% | -26% | -18.4% | 17.7% |
| Net Profit | -137.5 | 271.7 | 302.4 | -20.4 | 4,613.7 | 453.7 | 595.1 | 413.8 | 147.8 | 330.2 |
| EPS in Rs | -4.87 | 9.63 | 10.72 | -0.72 | 163.5 | 16.08 | 21.09 | 14.66 | 0 | 11.7 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,463.9 | 3,373.7 | 3,401.6 | 3,207.4 | 2,506.7 | 3,063.0 | 3,244.2 | 3,433.8 | 3,387.6 | 3,256.2 |
| Expenses | 2,843.6 | 2,768.7 | 2,770.4 | 2,745.1 | 2,715.4 | 2,558.6 | 2,656.0 | 2,831.9 | 2,787.3 | 2,695.1 |
| Operating Profit | 620.2 | 605.0 | 631.2 | 462.3 | -208.6 | 504.3 | 588.2 | 601.9 | 600.2 | 561.1 |
| OPM % | 17.91% | 17.93% | 18.56% | 14.41% | -8.32% | 16.47% | 18.13% | 17.53% | 17.72% | 17.23% |
| Other Income | 110.3 | -839.9 | -31.2 | -323.7 | -31.3 | 326.4 | 31.5 | 39.4 | 31.1 | -361.1 |
| Interest | 97.3 | 109.3 | 112.0 | 121.5 | 134.3 | 148.6 | 39.6 | 48.5 | 52.3 | 66.7 |
| Depreciation | 162.3 | 146.5 | 154.7 | 141.5 | 147.1 | 151.3 | 117.8 | 120.3 | 122.7 | 125.2 |
| Profit before tax | 437.1 | 309.0 | 385.4 | 201.1 | -444.7 | 977.6 | 462.3 | 472.6 | 456.3 | 380.9 |
| Tax % | -38.3% | -17.9% | -48.1% | 45% | -13.8% | -333.3% | 26.4% | 25% | 23.7% | -43.9% |
| Net Profit | 290.8 | -403.1 | 173.1 | -63.6 | -330.8 | -1,214.3 | 340.2 | 354.5 | 348.0 | 4.4 |
| EPS in Rs | 9.66 | -15.18 | 5.31 | -2.9 | -12.45 | -43.18 | 12.06 | 12.55 | 12.33 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 5% |
| 3 Years: | 1% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 1% |
| 3 Years: | -4% |
| TTM: | 119% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 32% |
| 3 Years: | 54% |
| 1 Year: | 39% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 4% |
| 3 Years: | 3% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | -5102% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 32% |
| 3 Years: | 54% |
| 1 Year: | 39% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|